NCT00539929

Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis

Proof of Principle, Randomized, Parallel-Group, Double-Blind, Vehicle-Controlled, Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Eisai Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a double-blind, multicenter study to assess the efficacy and safety of E6201 topical administration to pre-identified marker lesions in adult subjects with chronic plaque type psoriasis. Treatment duration is 8 weeks, followed by a 4-week period without treatment. Pharmacokinetic samples will be obtained pre-and post treatment.

Conditions

• Chronic Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	E6201 0.005%
DRUG	E6201 0.01%
DRUG	E6201 0.03%
DRUG	Placebo

Timeline

• Start date: 2007-09-01
• Primary completion: 2008-06-01
• Completion: 2008-07-01
• First posted: 2007-10-05
• Last updated: 2017-02-06

Locations

12 sites across 1 country: United States